MK-677

MK-677 (Ibutamoren) is a non-peptide, orally active ghrelin mimetic and growth hormone secretagogue developed by Merck & Co. in the 1990s. It acts as a selective agonist of the ghrelin receptor (GHSR-1a), the same receptor targeted by injectable GHRPs like Ipamorelin, but with the crucial advantage of oral bioavailability — it can be taken as a capsule or tablet rather than requiring injection.

Despite being classified as a "growth hormone secretagogue," MK-677 is technically a small molecule drug rather than a peptide. However, it is consistently discussed alongside peptides in the research and performance communities because it occupies the same pharmacological space and is used for similar purposes.

MK-677 was studied extensively by Merck for treatment of conditions including growth hormone deficiency, muscle wasting (cachexia), osteoporosis, and Alzheimer's disease. Although it demonstrated significant effects on GH and IGF-1 in clinical trials, Merck ultimately did not advance it to regulatory approval for any indication. The reasons included mixed results on primary endpoints in some trials and the development of safer alternatives.

MK-677 is not FDA-approved and is frequently classified as a "research chemical." Importantly, it is NOT a SARM (selective androgen receptor modulator) despite being frequently marketed alongside them. Its mechanism is entirely different — it does not interact with androgen receptors.

MK-677 acts through ghrelin receptor agonism:

• Ghrelin receptor (GHSR-1a) agonism: MK-677 binds with high affinity to GHSR-1a receptors in the pituitary, hypothalamus, and throughout the body. In the pituitary, this triggers GH secretion; in the hypothalamus, it influences appetite and GH regulatory signaling.
• Dual GH-stimulating mechanism: MK-677 stimulates GH release through two mechanisms: direct pituitary stimulation via GHSR-1a, and amplification of hypothalamic GHRH secretion. This dual action may explain its potency relative to peptide GHRPs.
• Sustained GH elevation: Unlike injectable GHRPs that produce acute GH pulses, MK-677's oral bioavailability and longer half-life (approximately 24 hours) provide sustained elevation of GH over 24 hours, maintaining elevated IGF-1 levels throughout the day.
• IGF-1 stimulation: The sustained GH elevation reliably elevates IGF-1, often significantly — clinical trials have documented 60–80% increases in IGF-1 from baseline in some studies.
• Preserved somatostatin regulation: MK-677 appears to reduce sensitivity to somatostatin (GH-inhibiting hormone), allowing more GH to be released, while still preserving some feedback regulation.

MK-677 has been studied in several clinical contexts, providing more human data than most GH-stimulating peptides:

• Muscle mass: Clinical trials in older adults show significant increases in lean body mass and muscle strength, making it relevant to sarcopenia (age-related muscle loss) prevention and treatment.
• Bone density: Merck's clinical research demonstrated improvements in bone mineral density in postmenopausal women and elderly men, consistent with GH/IGF-1's anabolic effects on bone.
• GH deficiency treatment: Studies in GH-deficient adults showed MK-677 restored IGF-1 to normal ranges, validating its mechanism.
• Metabolic effects: Body composition improvements including fat loss (particularly visceral fat) and lean mass gain are documented in clinical trials.
• Sleep quality: Clinical studies document increases in REM sleep and stage IV (deep) sleep with MK-677, potentially related to GH's role in sleep architecture regulation.
• Wound healing: GH and IGF-1 support tissue repair; animal and some human data suggest improved healing.
• Neuroprotection (Alzheimer's): Phase II trials were conducted for Alzheimer's disease, though results were mixed and the indication was not pursued further.

MK-677 has more clinical trial safety data than most research peptides, allowing a more evidence-based discussion of side effects:

• Water retention: One of the most commonly reported and documented side effects; GH's sodium-retaining effects cause fluid accumulation, particularly noticeable early in use
• Increased appetite: As a ghrelin mimetic, MK-677 frequently stimulates appetite significantly, which can counteract fat loss goals and contributes to weight gain beyond lean mass
• Lethargy and fatigue: A well-documented effect, particularly in the first weeks of use; often described as a "heaviness" — may relate to increased GH effects on daytime CNS function
• Insulin resistance: Clinical trials documented statistically significant increases in fasting blood glucose and HbA1c (a long-term glucose marker) — a meaningful concern for metabolic health and diabetes risk
• Joint pain: Reported in clinical trials at higher doses
• Carpal tunnel syndrome: Fluid accumulation in the carpal tunnel is a recognized GH side effect, reported with MK-677
• Potential IGF-1 elevation concerns: Chronically elevated IGF-1 has epidemiological associations with some cancers; the clinical significance for MK-677 users is uncertain

The insulin resistance finding is particularly important and warrants monitoring of blood glucose during MK-677 use.

Disclaimer: MK-677 is not FDA-approved for human use. The following references clinical trial and research community dosing.

Dosing details:

• Clinical trial doses: Most clinical trials used 25 mg/day orally; some studies evaluated 10–50 mg/day ranges
• Research community dose: 10–25 mg per day orally, with 12.5–25 mg being most commonly reported
• Timing: Typically taken once daily before bed to minimize daytime lethargy and leverage nocturnal GH release patterns
• Cycle length: MK-677's longer-term safety profile (from clinical trials) supports extended use more than most research peptides; some researchers use it for several months to a year; others prefer 3–6 month cycles with breaks

The oral route is MK-677's primary advantage over injectable GH peptides. No reconstitution or injections are required.

MK-677 has an unusually comprehensive clinical research base for a research chemical:

• Elderly muscle/bone trials: Merck-funded trials in healthy older adults documented significant IGF-1 elevation, improved lean mass, and bone density improvements over 6–12 month periods — providing relatively long-term human data.
• GH deficiency trials: Studies in GH-deficient adults confirmed dose-dependent IGF-1 restoration and body composition improvements.
• Alzheimer's trial: A Phase II study assessed whether GH/IGF-1 restoration could improve cognition in mild-to-moderate Alzheimer's disease. While IGF-1 was effectively elevated, cognitive endpoints were not significantly improved.
• Sleep studies: Controlled studies documented REM and stage IV sleep enhancement, providing objective evidence of CNS activity.
• Insulin resistance documentation: Clinical trials prospectively documented the insulin-desensitizing effects of MK-677, establishing this as a real rather than theoretical concern.

MK-677's clinical data makes it one of the better-characterized research peptide/secretagogues from a human safety and pharmacology standpoint, though it was ultimately not approved by any major regulatory agency for any indication.